These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21640689)

  • 1. The effect of eprosartan on reflex sympathetic activation in sodium restricted patients with essential hypertension.
    Vase H; Lauridsen TG; Graffe CC; Pedersen EB
    J Am Soc Hypertens; 2011; 5(5):385-94. PubMed ID: 21640689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans.
    Vase H; Lauridsen TG; Bech JN; Pedersen EB
    Br J Clin Pharmacol; 2008 Jun; 65(6):822-32. PubMed ID: 18341678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
    Brooks DP; Ruffolo RR
    J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of eprosartan on the sympathetic response to cold pressor test in healthy volunteers.
    Israel A; Zavala LE; Cierco M; Gutierrez A; del Rosario Garrido M
    Auton Neurosci; 2006 Jun; 126-127():179-84. PubMed ID: 16630748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of AT(1) angiotensin II receptor antagonists on the sympathetic response to a cold pressor test in healthy volunteers.
    Israel A; Zavala LE; Cierco M; Gutierrez A; Garrido Mdel R
    Am J Ther; 2007; 14(2):183-8. PubMed ID: 17414588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study.
    Punzi HA; Punzi CF
    J Hum Hypertens; 2004 Sep; 18(9):655-61. PubMed ID: 15042114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A; Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Heusser et al: elevation of sympathetic activity by eprosartan in young male subjects.
    Rupp H
    Am J Hypertens; 2004 Mar; 17(3):281; author reply 281-3. PubMed ID: 15001205
    [No Abstract]   [Full Text] [Related]  

  • 10. AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.
    Heusser K; Vitkovsky J; Schmieder RE; Schobel HP
    Auton Neurosci; 2003 Aug; 107(1):45-51. PubMed ID: 12927226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
    Levine B
    Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of the renin-angiotensin system on the sympathetic response induced by the cold pressor test in humans].
    Zavala LE; Cierco M; Gutiérrez A; Garrido MR; Israel A
    Invest Clin; 2007 Jun; 48(2):155-65. PubMed ID: 17598639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure.
    Neumann J; Ligtenberg G; Oey L; Koomans HA; Blankestijn PJ
    J Am Soc Nephrol; 2004 Nov; 15(11):2902-7. PubMed ID: 15504943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevation of sympathetic activity by eprosartan in young male subjects.
    Heusser K; Vitkovsky J; Raasch W; Schmieder RE; Schobel HP
    Am J Hypertens; 2003 Aug; 16(8):658-64. PubMed ID: 12878372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men.
    Ilson BE; Boike SC; Martin DE; Freed MI; Zariffa N; Jorkasky DK
    Clin Pharmacol Ther; 1998 Apr; 63(4):471-81. PubMed ID: 9585802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
    Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
    Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity.
    Dhakam Z; McEniery CM; Yasmin ; Cockcroft JR; Brown MJ; Wilkinson IB
    Am J Hypertens; 2006 Feb; 19(2):214-9. PubMed ID: 16448896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AT1 blockers and uric acid metabolism: are there relevant differences?
    Puig JG; Torres R; Ruilope LM
    J Hypertens Suppl; 2002 Jun; 20(5):S29-31. PubMed ID: 12184060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pressure-dependent distal tubular action of atrial natriuretic peptide in healthy humans.
    Eiskjaer H; Nielsen CB; Pedersen EB
    J Hypertens; 1996 Jan; 14(1):99-106. PubMed ID: 12013501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does blockade of the renin angiotensin system affect sympathetic and blood pressure responses to amlodipine in young hypertensive patients?
    Ruzicka M; Coletta E; Leenen FH
    Am J Hypertens; 2007 Nov; 20(11):1202-8. PubMed ID: 17954368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.